Clinical Diagnostics

Comprehensive Clinical Test Catalogue

Advanced Diagnostic Solutions for Precision Medicine

NABL-accredited laboratory offering 93 specialized diagnostic tests across 11 clinical specialties. From prenatal genetics to infectious disease detection, we provide accurate, timely results that guide critical healthcare decisions.

93
Diagnostic Tests
11
Specialties
NABL
Accredited
Clinical Laboratory

Oncology & Cancer Genomics

Comprehensive tumor profiling and hereditary cancer risk panels using advanced next-generation sequencing for precision oncology.

MDB-ONC-001

OncoFocus

Targeted tumor profiling panel for solid-tumor somatic mutation analysis. Interrogates key cancer-driving genes and actionable variants to guide therapy selection and prognostic stratification.

MethodologyHybrid-capture or amplicon-based NGS panel
SampleFFPE Block Section
TAT25 Days
MDB-ONC-002

OncoFocus LB

Liquid-biopsy version of OncoFocus, optimized for circulating tumor DNA (ctDNA) analysis. Enables non-invasive mutation profiling and disease monitoring from plasma.

MethodologyctDNA-optimized NGS panel
SampleWhole Blood Streck Tube
TAT25 Days
MDB-ONC-003

Comprehensive Onco Profile

Broad-coverage tumor genomic profile assessing SNVs, indels, CNVs, and selected fusions across a large oncogene panel. Supports comprehensive biomarker discovery and therapy matching.

MethodologyWhole-exome-style or extended targeted NGS panel
SampleFFPE Block Section
TAT25 Days
MDB-ONC-004

OncoFusion Panel

RNA-based NGS panel for detecting clinically relevant gene fusions and rearrangements in hematologic malignancies and solid tumors.

MethodologyTargeted RNA-sequencing (fusion-focused panel)
SampleFFPE Block
TAT18 Days
MDB-ONC-005

Hereditary Onco Screen

Germline panel for inherited cancer-predisposing genes across multiple hereditary cancer syndromes (e.g., BRCA1/2, Lynch, etc.).

MethodologyTargeted germline NGS panel
SampleWhole Blood in EDTA Tube
TAT18 Days
MDB-ONC-006

HRD PLUS

Homologous recombination deficiency (HRD)-oriented panel assessing genomic instability,BRCA1/2 status, and related DNA-repair genes. Used for PARPi eligibility and genetic risk assessment.

MethodologyNGS-based HRD scoring + targeted gene panel
SampleFFPE Block
TAT18 Days
MDB-ONC-007

Mutation Tracker MRD

Ultra-sensitive, patient-specific minimal residual disease (MRD) assay for tracking tumor-specific variants over time. Enables early detection of recurrence and treatment response monitoring.

MethodologyDigital droplet PCR or NGS-based personalized MRD assay
SampleWhole Blood in Streck Tube
TAT18 Days